Free Trial

TG Therapeutics (TGTX) Competitors

TG Therapeutics logo
$34.65 -0.22 (-0.63%)
As of 10:48 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

TGTX vs. GMAB, SMMT, ASND, RDY, VTRS, ROIV, BBIO, MRNA, QGEN, and ELAN

Should you be buying TG Therapeutics stock or one of its competitors? The main competitors of TG Therapeutics include Genmab A/S (GMAB), Summit Therapeutics (SMMT), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Viatris (VTRS), Roivant Sciences (ROIV), BridgeBio Pharma (BBIO), Moderna (MRNA), QIAGEN (QGEN), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

TG Therapeutics vs. Its Competitors

TG Therapeutics (NASDAQ:TGTX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

TG Therapeutics has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Genmab A/S has higher revenue and earnings than TG Therapeutics. Genmab A/S is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$329M16.71$23.38M$0.3793.65
Genmab A/S$3.12B6.74$1.14B$1.9916.48

In the previous week, Genmab A/S had 27 more articles in the media than TG Therapeutics. MarketBeat recorded 28 mentions for Genmab A/S and 1 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.78 beat Genmab A/S's score of 0.66 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
8 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

TG Therapeutics currently has a consensus target price of $49.00, indicating a potential upside of 41.41%. Genmab A/S has a consensus target price of $40.80, indicating a potential upside of 24.41%. Given TG Therapeutics' higher possible upside, equities analysts plainly believe TG Therapeutics is more favorable than Genmab A/S.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
Genmab A/S
1 Sell rating(s)
2 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.82

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 10.6% of TG Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Genmab A/S has a net margin of 37.53% compared to TG Therapeutics' net margin of 13.31%. TG Therapeutics' return on equity of 26.05% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics13.31% 26.05% 9.58%
Genmab A/S 37.53%21.03%16.98%

Summary

Genmab A/S beats TG Therapeutics on 9 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TGTX vs. The Competition

MetricTG TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$5.48B$3.42B$6.10B$10.49B
Dividend YieldN/A2.29%5.73%4.78%
P/E Ratio93.3923.0484.6327.17
Price / Sales16.71484.44608.51132.45
Price / Cash292.1746.9737.8662.13
Price / Book24.2310.5112.356.62
Net Income$23.38M-$52.47M$3.33B$276.88M
7 Day Performance2.64%3.06%2.11%1.49%
1 Month Performance8.15%15.52%9.40%4.79%
1 Year Performance44.74%13.77%73.46%36.32%

TG Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TGTX
TG Therapeutics
4.4125 of 5 stars
$34.65
-0.6%
$49.00
+41.4%
+42.3%$5.48B$329M93.39290
GMAB
Genmab A/S
3.7565 of 5 stars
$32.68
+2.7%
$40.80
+24.8%
+44.9%$20.42B$3.12B16.422,682Trending News
Analyst Forecast
Short Interest ↑
Analyst Revision
SMMT
Summit Therapeutics
3.0162 of 5 stars
$22.93
+7.4%
$31.29
+36.4%
-6.4%$15.86B$700K-22.70110Upcoming Earnings
ASND
Ascendis Pharma A/S
2.8766 of 5 stars
$208.43
-0.5%
$248.29
+19.1%
+58.9%$12.93B$393.54M-40.391,017News Coverage
Analyst Forecast
Analyst Revision
Gap Up
RDY
Dr. Reddy's Laboratories
3.1513 of 5 stars
$14.36
+0.1%
$16.95
+18.1%
-10.1%$11.97B$3.81B21.7527,811Positive News
VTRS
Viatris
3.1067 of 5 stars
$9.86
+1.2%
$10.40
+5.5%
-14.6%$11.36B$14.74B-3.4032,000News Coverage
Analyst Forecast
ROIV
Roivant Sciences
3.0735 of 5 stars
$16.21
+1.1%
$19.94
+23.0%
+42.9%$10.95B$29.05M-23.16860Insider Trade
BBIO
BridgeBio Pharma
4.4949 of 5 stars
$55.96
+0.8%
$63.94
+14.3%
+108.9%$10.61B$221.90M-13.68400Positive News
Analyst Revision
MRNA
Moderna
4.2459 of 5 stars
$26.74
-0.3%
$41.81
+56.4%
-52.8%$10.48B$3.24B-3.555,800Analyst Revision
Gap Down
QGEN
QIAGEN
4.1228 of 5 stars
$47.30
+1.0%
$49.40
+4.4%
+14.5%$10.41B$1.98B27.955,765
ELAN
Elanco Animal Health
2.5478 of 5 stars
$20.04
+1.4%
$19.14
-4.5%
+54.6%$9.82B$4.44B23.309,000Analyst Revision

Related Companies and Tools


This page (NASDAQ:TGTX) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners